Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510367
Status:
COMPLETED
Last Update Posted:
2020-07-10
First Post:
2007-07-31
Brief Title:
Primary Breast Cancer Occurring Concomitant With Pregnancy
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
Multimodality Treatment of Primary Breast Cancer Occurring Concomitant With Pregnancy
Status:
COMPLETED
Status Verified Date:
2020-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to learn the results of multimodality chemotherapy surgery and radiation therapy treatment of primary breast cancer that occurs at the same time as pregnancy Researchers want to evaluate the outcome of labor and delivery as well as evaluate the long-term health outcomes of children exposed to chemotherapy while in their mothers womb
Detailed Description:
Patients in this study will be evaluated by the Department of Breast Medical Oncology attending physician and the obstetrician Patients who do not have an obstetrician will be referred to an obstetrician or Maternal-Fetal Medicine specialist for evaluation
Counseling about primary breast cancer risks staging evaluation and breast cancer management will be provided by members of the Department of Breast Medical Oncology Counseling about fetal health risks will be provided by the medical oncologists and the obstetrician or the Maternal-Fetal Medicine Specialist Counseling about surgical risks will be provided by the Breast Surgical Service Evaluation will include a medical history and physical exam Doctors will be evaluating patients especially for the presence of metastatic disease The date of the last menstrual period and estimated date of delivery will be recorded
Patients in this study will have a chest radiograph with appropriate fetal shielding Patients will have an ultrasound of the abdomen to evaluate the presence or absence of metastatic disease in the liver If suspicious abnormalities are found a MRI of the abdomen will be done Scanning MRI of the thoracic spine will be performed to screen for bone metastases Patients will have standard blood tests and a mammogram or ultrasound of the affected breast and lymph node bearing areas Patients will have a tissue biopsy to confirm the status of the cancer An ultrasound will also be performed to learn the age and development of the fetus
Patients with operable primary breast cancer tumors will have surgical evaluation for surgical therapy with modified radical mastectomy or segmental mastectomy with lymph node dissection
Patients with locally advanced breast cancers will receive systemic multi-agent chemotherapy in the presurgical setting
Patients will have physical exams mammograms and ultrasounds repeated to evaluate tumor response to treatment All patients who will receive chemotherapy will be offered systemic chemotherapy with 5-fluorouracil doxorubicin and cyclophosphamide FAC
Patients will be followed 6-12 months using the American Society of Clinical Oncology Guidelines and the Surveillance Committee Guidelines All children will be followed until their adulthood If the disease gets worse patients will be treated off the study with individualized therapy Premedication will be provided for all patients in order to decrease the risks of nausea and vomiting When needed adjustment in dosage of chemotherapy or modification in the way the medicines are given will be made in order to decrease any side effects
This is an investigational study The FDA has approved the study drugs Their use together in this study is experimental At least 100 patients will take part in this study All will be enrolled at MD Anderson
Counseling about primary breast cancer risks staging evaluation and breast cancer management will be provided by members of the Department of Breast Medical Oncology Counseling about fetal health risks will be provided by the medical oncologists and the obstetrician or the Maternal-Fetal Medicine Specialist Counseling about surgical risks will be provided by the Breast Surgical Service Evaluation will include a medical history and physical exam Doctors will be evaluating patients especially for the presence of metastatic disease The date of the last menstrual period and estimated date of delivery will be recorded
Patients in this study will have a chest radiograph with appropriate fetal shielding Patients will have an ultrasound of the abdomen to evaluate the presence or absence of metastatic disease in the liver If suspicious abnormalities are found a MRI of the abdomen will be done Scanning MRI of the thoracic spine will be performed to screen for bone metastases Patients will have standard blood tests and a mammogram or ultrasound of the affected breast and lymph node bearing areas Patients will have a tissue biopsy to confirm the status of the cancer An ultrasound will also be performed to learn the age and development of the fetus
Patients with operable primary breast cancer tumors will have surgical evaluation for surgical therapy with modified radical mastectomy or segmental mastectomy with lymph node dissection
Patients with locally advanced breast cancers will receive systemic multi-agent chemotherapy in the presurgical setting
Patients will have physical exams mammograms and ultrasounds repeated to evaluate tumor response to treatment All patients who will receive chemotherapy will be offered systemic chemotherapy with 5-fluorouracil doxorubicin and cyclophosphamide FAC
Patients will be followed 6-12 months using the American Society of Clinical Oncology Guidelines and the Surveillance Committee Guidelines All children will be followed until their adulthood If the disease gets worse patients will be treated off the study with individualized therapy Premedication will be provided for all patients in order to decrease the risks of nausea and vomiting When needed adjustment in dosage of chemotherapy or modification in the way the medicines are given will be made in order to decrease any side effects
This is an investigational study The FDA has approved the study drugs Their use together in this study is experimental At least 100 patients will take part in this study All will be enrolled at MD Anderson
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-2012-01578 | REGISTRY | NCI CTRP | None |